The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat

Metabolism: Clinical and Experimental

Volumn 46, Issue 8, 1997, Pages 935-942

  Oakes, Nicholas D ^a   Camilleri, Souad ^a   Furler, Stuart M ^a   Chisholm, Donald J ^a   Kraegen, Edward W ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; PEROXISOME PROLIFERATOR; RECEPTOR; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOGENESIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

EID: 0030811602     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90083-4     Document Type: Article

References (49)

1. Randle PJ, Garland PB, Hales CN, et al: The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-794, 1963
2. Ruderman NB, Toews CJ, Shafrir E: Role of free fatty acids in glucose homeostasis. Arch Intern Med 123:299-313, 1969
3. Hofmann CA, Colca JR: New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 15:1075-1078, 1992
4. Bressler R, Johnson D: New pharmacological approaches to therapy of NIDDM. Diabetes Care 15:792-803, 1992
5. Lehmann JM, Moore LB, Smith-Oliver TA, et al: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ(PPARγ). J Biol Chem 270:12953-12956, 1995
6. Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302:93-109, 1996
7. Grundleger ML, Thenen WS: Decreased insulin binding, glucose transport, and glucose metabolism in soleus muscle of rats fed a high fat diet. Diabetes 31:232-237, 1982
8. Storlien L, James DE, Burleigh KM, et al: Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol 251:E567-E583, 1986
9. 2+ and phospholipid-activated protein kinase (protein kinase C). J Biol Chem 267:12673-12681, 1984
10. Considine RV, Caro JF: Protein kinase C: Mediator or inhibitor of insulin action? J Cell Biochem 52:8-13, 1993
11. Danielsen AG, Liu F, Hosomi Y, et al: Activation of protein kinase C inhibits signaling by members of the insulin receptor family. J Biol Chem 270:21600-21605, 1995
12. Nishizuka Y: Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9:484-496, 1995
13. Cooper DR, Watson JE, Dao ML: Decreased expression of protein kinase-C, α, β, ε in soleus muscle of Zucker obese (fa/fa) rats. Endocrinology 133:2241-2247, 1993
14. Oakes ND, Kennedy CK, Jenkins AB, et al: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action in the rat. Diabetes 43:1203-1210, 1994
15. Kraegen EW, Clark PW, Jenkins AB, et al: Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40:1397-1403, 1991
16. Reeves PG: AIN-76 diet: Should we change the formulation? J Nutr 119:1081-1082, 1986
17. Hagenfeldt L: A gas Chromatographic method for the determination of individual free fatty acids in plasma. Clin Chim Acta 13:266-268, 1966
18. Otway S, Robinson DS: The use of non-ionic detergent (Triton WR-1339) to determine rates of triglyceride entry into the circulation of the rats under different physiological conditions. J Physiol (Lond) 190:321-332, 1967
19. Kraegen EW, James DE, Bennet SP, et al: In vivo insulin sensitivity in the rat determined by the euglycaemic clamp. Am J Physiol 245:E1-E7, 1983
20. Kraegen EW, James DE, Jenkins AB, et al: Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol 248:E353-E362, 1985
21. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509, 1957
22. Nakamura K, Handa S: Coomassie brilliant blue staining of lipids on thin-layer plates. Anal Biochem 142:406-410, 1984
23. Sokal RR, Rohlf FJ: Biometry. San Francisco, CA, Freeman, 1969
24. Duerden JM, Gibbons GF: Secretion and storage of newly synthesized hepatic triacylglycerol fatty acids in vivo in different nutritional states and diabetes. Biochem J 255:929-935, 1988
25. Jenkins AB, Storlien LH, Chisholm DJ, et al: Effects of nonesterified fatty acid availability on tissue-specific glucose utilization in rats in vivo. J Clin Invest 82:293-299, 1988
26. 14C as esterified fatty acid in the plasma of rats and turnover rate of plasma triglycerides. Acta Physiol Scand 47:218-232, 1959
27. Baker N, Gan-Elepano M, Guthrie BA, et al: Delayed recycling of plasma FFA in mice: Revised model of turnover and oxidation. Am J Physiol 253:R746-R755, 1987
28. Storlien LH, Jenkins AB, Chisholm DJ, et al: Influence of dietary fat composition on development of insulin resistance in rats. Diabetes 40:280-289, 1991
29. Storlien LH, Oakes ND, Pan DA, et al: Syndromes of insulin resistance in the rat. Inducement by diet and amelioration with benfluorex. Diabetes 42:457-462, 1993
30. Fujita T, Sugiyama Y, Taketomi S, et al: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32:804-810, 1983
31. Fujiwara T, Yoshioka S, Yoshioka T, et al: Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
32. Stevenson RW, Hutson NJ, Krupp MN, et al: Actions of novel antidiabetic agent englitazone in hyperglycemic ob/ob mice. Diabetes 39:1218-1227, 1990
33. Ikeda H, Takemori S, Sugiyama Y, et al: A new oral hypoglycemic agent, 5-[4-[2-(5-ethyl-2-pyrudyl)ethoxyl]benzyl] 2,4-thiazolidinedione (AD-4833, U-72, 102E, pioglitazone). I. Effects on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 40:156-162, 1990
34. Gibbons GF, Burnham FJ: Effect of nutritional state on the utilization of fatty acids for hepatic triacylglycerol synthesis and secretion as very-low-density lipoprotein. Biochem J 275:87-92, 1991
35. Kobayashi M, Iwanishi M, Egawa K, et al: Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 41:476-483, 1992
36. Suter SL, Nolan JJ, Wallace P, et al: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
37. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
38. Heydrick SJ, Ruderman NB, Kurowski TG, et al: Enhanced stimulation of diacylglycerol and lipid synthesis by insulin in denervated muscle. Diabetes 40:1707-1711, 1991
39. Saha AK, Kurowski TG, Colca JR, et al: Lipid abnormalities in tissues of the KKAy mouse: Effects of pioglitazone on malonyl-CoA and diacylglycerol. Am J Physiol 267:E95-E101, 1994
40. Kimball TJ, Childs MT, Applebaum-Bowden D, et al: The effect of training and diet on lipoprotein cholesterol, tissue lipoprotein lipase and hepatic triglyceride lipase in rats. Metabolism 32:497-503, 1983
41. Kiens B, Essen-Gustavsson B, Gad P, et al: Lipoprotein lipase activity and intramuscular triglyceride stores after long-term high-fat and high-carbohydrate diets in physically trained men. Clin Physiol 7:1-9, 1987
42. Tan MH, Sata T, Havel RJ: The significance of lipoprotein lipase in rat skeletal muscles. J Lipid Res 18:363-370, 1977
43. Ailhaud G, Grimaldi P, Negrel R: Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr 12:207-233, 1992
44. De Vos P, Lefebvre AM, Miller SG, et al: Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98:1004-1009, 1996
45. Zhang B, Graziano MP, Doebber TW, et al: Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 271:9455-9459, 1996
46. Nolan JJ, Ludvik B, Beerdsen P, et al: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
47. Iwamoto Y, Kosaka K, Kuzuya T, et al: Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 19:151-156, 1996
48. Jacquez JA: Compartmental Analysis in Biology and Medicine. Ann Arbor, MI, University of Michigan Press, 1985
49. Press WH, Flannery BP, Teukolsky SA, et al: Numerical Recipes. Cambridge, UK, Cambridge University Press, 1986